Italia markets close in 5 hours 31 minutes

Acasti Pharma Inc. (ACST)

NasdaqCM - NasdaqCM Prezzo differito. Valuta in USD.
Aggiungi a watchlist
2,9000+0,0300 (+1,05%)
Alla chiusura: 04:00PM EDT
3,0100 +0,11 (+3,79%)
Dopo ore: 06:35PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente2,8700
Aperto2,8710
Denaro0,0000 x 0
Lettera0,0000 x 0
Min-Max giorno2,8710 - 3,1600
Intervallo di 52 settimane1,7200 - 3,8400
Volume8.415
Media Volume26.350
Capitalizzazione27,258M
Beta (5 anni mensile)1,52
Rapporto PE (ttm)N/D
EPS (ttm)-5,6800
Prossima data utili21 giu 2024 - 25 giu 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A6,03
  • GlobeNewswire

    Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)

    Virtual Webinar to Take Place October 11, 2023 at 2:00pm ETPRINCETON, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that it will host a virtual KOL event titled GTX-104: a potential new treatment standard for rare and life-threatening aS

  • GlobeNewswire

    Acasti Announces $7.5 Million Private Placement Equity Financing

    PRINCETON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that it has closed a private placement of the Company's securities pursuant to the terms of a securities purchase agreement, dated September 24, 2023, by and between the Company a

  • GlobeNewswire

    Acasti to Participate in the H.C. Wainwright Global Investment Conference

    PRINCETON, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that the Company’s management will be participating in the 25th Annual H.C. Wainwright Global Investment Conference, to be held September 11-13 , 2023 in New York, NY. Prashant Ko